First Tracks Biotherapeutics (TRAX)

• Market cap: $634M
• 1 day: 6.01%
• 5 days: 12.58%
• 1 month: 2.14%
• 3 months: -4.37%
• 6 months: -4.37%
• Year to date: -4.37%
• 1 year: -4.37%
• 5 years: -4.37%
• 10 years: -4.37%
• Sector: Healthcare
• Industry: Biotechnology

About: First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.